Interferon-α Maintenance in Favorable-Risk AML

Acute myeloid leukemia (AML) is a blood cancer with a substantial risk of relapse after initial treatment. Although patients with favorable-risk AML generally have better outcomes, relapse remains a major concern. Interferon-alpha (IFN-α) may help prevent relapse, but its effectiveness as maintenance therapy has not been confirmed in prospective studies. This prospective, single-arm study aims to evaluate the efficacy and safety of IFN-α as maintenance therapy in patients with favorable-risk AML. Participants will receive IFN-α maintenance treatment and will be followed for disease relapse, s

Trial Details

NCT ID
NCT07925554
Phase
PHASE2
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • pegylated interferon alfa-2b
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 18-70 years, inclusive.
  • Newly diagnosed favorable-risk acute myeloid leukemia (AML) according to the 2022 European LeukemiaNet (ELN) risk classification.
  • Achieved first complete remission (CR1) after 1-2 courses of standard chemotherapy.
  • Completed 4-6 courses of consolidation chemotherapy, including at least 2 courses of high-dose cytarabine (HiDAC).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →